Bank of America (BofA) has reiterated its buy rating on Dr Reddy’s Laboratories, setting a target price of ₹1,530, suggesting a 20% upside from the current market price of ₹1,276.90. The brokerage highlighted strong, all-around growth as a key driver for Dr Reddy’s EBITDA beat, supported by sustained revenue momentum.
BofA noted positive updates on core growth drivers and emphasized that Dr Reddy’s has multiple levers to address the revenue impact from the generic Revlimid (gRevlimid) gap. The company’s diversified growth strategy positions it well to maintain momentum across various segments.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a financial advisor before making any investment decisions.
